These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25178921)

  • 21. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
    Doenhoff MJ; Pica-Mattoccia L
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):199-210. PubMed ID: 16597202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment.
    de Souza AL; Andreani T; de Oliveira RN; Kiill CP; dos Santos FK; Allegretti SM; Chaud MV; Souto EB; Silva AM; Gremião MP
    Int J Pharm; 2014 Mar; 463(1):31-7. PubMed ID: 24370839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical and experimental study of a praziquantel and beta-cyclodextrin inclusion complex using molecular mechanic calculations and H1-nuclear magnetic resonance.
    de Jesus MB; de Matos Alves Pinto L; Fraceto LF; Takahata Y; Lino AC; Jaime C; de Paula E
    J Pharm Biomed Anal; 2006 Jun; 41(4):1428-32. PubMed ID: 16678375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: is actin the praziquantel receptor?
    Tallima H; El Ridi R
    Int J Antimicrob Agents; 2007 Dec; 30(6):566-7. PubMed ID: 17900872
    [No Abstract]   [Full Text] [Related]  

  • 25. Resolution of praziquantel.
    Woelfle M; Seerden JP; de Gooijer J; Pouwer K; Olliaro P; Todd MH
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1260. PubMed ID: 21949890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of praziquantel on the immature stages of Schistosoma haematobium.
    Botros S; Pica-Mattoccia L; William S; El-Lakkani N; Cioli D
    Int J Parasitol; 2005 Nov; 35(13):1453-7. PubMed ID: 16002073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni.
    Liang YS; Coles GC; Dai JR; Zhu YC; Doenhoff MJ
    Ann Trop Med Parasitol; 2001 Oct; 95(7):715-23. PubMed ID: 11784425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and relative bioavailability of praziquantel in healthy water buffalo after oral and intramuscular administration.
    Sun Y; Bu SJ
    J Vet Pharmacol Ther; 2012 Dec; 35(6):618-22. PubMed ID: 22239339
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants.
    Li C; Cheng L; Zhang Y; Guo S; Wu W
    Int J Pharm; 2010 Feb; 386(1-2):23-9. PubMed ID: 19895876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis.
    Doenhoff MJ; Cioli D; Utzinger J
    Curr Opin Infect Dis; 2008 Dec; 21(6):659-67. PubMed ID: 18978535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthelmintic activity of the natural compound (+)-limonene epoxide against Schistosoma mansoni.
    Moraes Jd; Almeida AA; Brito MR; Marques TH; Lima TC; Sousa DP; Nakano E; Mendonça RZ; Freitas RM
    Planta Med; 2013 Mar; 79(3-4):253-8. PubMed ID: 23408270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo effects of hesperidin treatment on adult worms of Schistosoma mansoni.
    Allam G; Abuelsaad AS
    J Helminthol; 2014 Sep; 88(3):362-70. PubMed ID: 23656891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
    Coles GC; Liang YS; Doenhoff MJ
    Emerg Infect Dis; 2001; 7(6):1069-70. PubMed ID: 11747748
    [No Abstract]   [Full Text] [Related]  

  • 34. Susceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni.
    Liang YS; Wang W; Dai JR; Li HJ; Tao YH; Zhang JF; Li W; Zhu YC; Coles GC; Doenhoff MJ
    J Helminthol; 2010 Jun; 84(2):202-7. PubMed ID: 19765323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decades down the line: the viability of praziquantel for future schistosomiasis treatment.
    Cioli D; Basso A; Valle C; Pica-Mattoccia L
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):835-7. PubMed ID: 23030319
    [No Abstract]   [Full Text] [Related]  

  • 36. Diagnostic issues of acute schistosomiasis with Schistosoma mekongi in a traveler: a case report.
    Clerinx J; Cnops L; Huyse T; Tannich E; Van Esbroeck M
    J Travel Med; 2013; 20(5):322-5. PubMed ID: 23992575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High analgesic and anti-inflammatory in vivo activities of six new hybrids NSAIAs tetrahydropyran derivatives.
    Capim SL; Gonçalves GM; Dos Santos GC; Marinho BG; Vasconcellos ML
    Bioorg Med Chem; 2013 Oct; 21(19):6003-10. PubMed ID: 23953687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Dipterex effect on bilharzial life cycle.
    Galal EE; Shinnawy AM; Faik S
    J Egypt Med Assoc; 1965; 48():Suppl:115-26. PubMed ID: 5873668
    [No Abstract]   [Full Text] [Related]  

  • 39. A comparative study on the effect of praziquantel and triclabendazole on Vampirolepis nana in vitro.
    el-Sayad MH; Lotfy WM
    J Egypt Soc Parasitol; 2002 Apr; 32(1):219-28. PubMed ID: 12049257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Praziquantel.
    Cioli D; Pica-Mattoccia L
    Parasitol Res; 2003 Jun; 90 Supp 1():S3-9. PubMed ID: 12811543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.